Travere Therapeutics, Inc. (17R.F)

17.30 0.00 (0.00%) At close: 07:39PM CEST

Travere Therapeutics, Inc.

3611 Valley Centre Drive
Suite 300
San Diego, CA 92130
United States
888 969 7879
https://www.travere.com

Sector(s): 
Industry: 
Full-time employees: 380

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Eric M. Dube Ph.D.	President, CEO & Director	1.31M	N/A	1973
Mr. Christopher Cline C.F.A.	Chief Financial Officer	662.42k	N/A	1985
Ms. Elizabeth E. Reed J.D.	Senior VP, General Counsel & Corporate Secretary	665.87k	N/A	1971
Dr. William E. Rote Ph.D.	Senior VP and Head of Research & Development	697.95k	N/A	1963
Mr. Peter Heerma	Chief Commercial Officer	692.67k	N/A	1972
Ms. Sandra Calvin	SVP, Corporate Controller & Chief Accounting Officer	N/A	N/A	1966
Ms. Naomi Eichenbaum	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Charlotte Smith	Senior Vice President of Public Affairs	N/A	N/A	N/A
Ms. Angela Giannantonio	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Casey Logan	Chief Business Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Corporate governance

Travere Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 4. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.